This is a working overview of Heptapeptide, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-05-11. Anything still debated is marked as such rather than presented as settled.
Regulatory treatment varies by jurisdiction. In Russia the compound is a registered prescription product, while in the European Union and the United States it is generally handled as a research chemical without a marketing authorization. Suppliers therefore operate outside pharmaceutical oversight, and buyers rely on supplier documentation for purity and identity claims. Chain of custody and third-party testing are the main verification tools. Analysts note that the absence of a pharmacopoeial monograph for research-grade material limits standardization across vendors.
Purity assessment relies mainly on reverse-phase high-performance liquid chromatography with ultraviolet detection. Because the peptide lacks a strong chromophore, detection often uses backbone absorbance near 214 nm. Identity is confirmed by mass spectrometry, typically electrospray ionization or matrix-assisted laser desorption, comparing the measured mass against the expected value. Amino acid analysis can verify composition after acid hydrolysis. Diastereomer content and residual counterions are reported less often, although both can influence biological assays.
Lyophilized material is generally stable for extended periods when kept dry at or below minus twenty degrees Celsius. Working solutions are less stable, and common practice is to aliquot and freeze them so that repeated freeze-thaw cycles are avoided. Aqueous solutions are sensitive to pH extremes and to microbial growth, so short-term storage at refrigerator temperature is typical. Oxidation and hydrolysis are the principal degradation routes. Reconstitution with sterile water or a mild buffer is standard, and solutions should be protected from light.
Published clinical evidence is limited. Most controlled trials were conducted in Russia, enrolled modest numbers of participants, and appeared in Russian-language journals, which restricts independent verification. Reported outcomes include lower anxiety scores, improved attention and memory measures, and changes in fatigue ratings. Reviews written in English note methodological limitations such as small samples and inconsistent endpoints. Whether the compound produces clinically meaningful benefit relative to established anxiolytics is therefore an open question rather than an established finding.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a structural analogue of tuftsin, a naturally occurring tetrapeptide fragment of the immunoglobulin heavy chain. The added Pro-Gly-Pro tail was intended to slow enzymatic degradation and extend biological activity. In Russia it is registered as an anxiolytic nasal preparation, while regulators elsewhere have not approved it for clinical use.
| Property | Value | Notes |
|---|---|---|
| Typical purity report | 95% or higher by HPLC | Area percentage at 214 nm |
| Identity confirmation | Mass spectrometry | Electrospray or MALDI |
| Powder storage | -20 C, desiccated | Protect from light |
| Solution storage | 2-8 C short term | Freeze aliquots for longer |
| Quality document | Certificate of analysis | States method and value |
Laboratory work relies on standard behavioral paradigms. Rodents are tested in the elevated plus maze, open field, and passive avoidance tasks, with outcomes compared against diazepam or vehicle controls. Intranasal dosing is used most often because it bypasses first-pass metabolism, though intraperitoneal and intravenous routes also appear in published protocols. Biochemical endpoints include tissue BDNF concentrations, cytokine levels, and monoamine metabolites. Human data are limited to small Russian trials reporting reduced anxiety scores; most were not prospectively registered, and few employed independent outcome assessment.
Measuring peptide exposure inside the brain is technically difficult. Selank is degraded rapidly in plasma, and assays must separate intact peptide from fragments, which favors targeted mass spectrometry over immunoassays alone. Reported half-lives are short, on the order of minutes, so effects observed hours later are attributed to downstream signaling rather than to the parent compound. Blood-brain barrier permeability is debated and rarely quantified directly. Gaps include absent dose-response characterization, inconsistent reporting of purity, and almost no pharmacokinetic data from human participants.
Selank is studied chiefly as an animal-model anxiolytic with proposed secondary effects on memory and immune signaling. Reported mechanisms include modulation of the GABA-A receptor complex, inhibition of enkephalin-degrading enzymes, and shifts in monoamine turnover within limbic structures. Some experiments describe increased expression of brain-derived neurotrophic factor in the hippocampus after repeated dosing. No single molecular target has been confirmed, and the peptide does not bind any receptor with the selectivity typical of a conventional small-molecule drug. Mechanism therefore remains a set of hypotheses rather than an established pathway.
Lyophilised material kept dry at minus 20 degrees Celsius or colder is the most stable form, and suppliers commonly state a shelf life of two years or more under those conditions. Once dissolved, degradation accelerates through hydrolysis and deamidation, particularly at alkaline pH or elevated temperature. Working solutions are usually divided into single-use aliquots to avoid repeated freeze-thaw cycles. The choice of reconstitution solvent affects both stability and the ionic strength of the final preparation.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres is the standard purity method. Mass spectrometry, typically electrospray ionisation, confirms identity through the expected mass-to-charge pattern. Amino acid analysis can verify composition independently. Chiral purity requires separate techniques such as derivatisation followed by chromatographic separation, and such data are rarely reported for research-grade material.
acid dissociation constant (Ka) Also acid ionization constant or acidity constant. A quantitative measure of the strength of an acid in solution expressed as an equilibrium constant for a chemical dissociation reaction in the context of acid-base reactions. It is often given as its base-10 cologarithm, pKa.
== Collagen fibre bundle splitting == The action of liming, in particular the swelling of the skin, results in the splitting of the fibre bundle sheath. Owing to the fibre diameter increasing, the bundle sheath cannot contain the thicker fibres, and it bursts open. This allows increased access to the fibres, which allows better tanning, retanning, dyeing and fatliquoring.
Hard ionization techniques are those that impart high quantities of residual internal energy in the subject molecule, even after ionization. Part of the energy would be dissipated by rupturing chemical bonds within the ion, producing many fragmentary radical cations. The resultant ions tend to have m/z lower than the molecular ion (other than in the case of proton transfer and not including isotope peaks). The most common example of hard ionization is electron ionization (EI). The radical ions produced after the first ionization are called second-generation product ions. The products are then directed towards the mass analyzer by a repeller electrode. The ionization process often follows predictable cleavage reactions that give rise to fragment ions which, following detection and signal processing, convey structural information about the analyte. Conversely, soft ionization techniques are those that impart little residual energy onto the subject molecule and as such result in little fragmentation. Examples include fast atom bombardment (FAB), chemical ionization (CI), atmospheric-pressure chemical ionization (APCI), atmospheric-pressure photoionization (APPI), electrospray ionization (ESI), desorption electrospray ionization (DESI), and matrix-assisted laser desorption/ionization (MALDI).
The Christian New Testament notes that some people thought that Jesus was, in some sense, Elijah, but it also makes clear that John the Baptist is "the Elijah" who was promised to come in Malachi 3:1; 4:5. According to accounts in all three of the Synoptic Gospels, Elijah appeared with Moses during the Transfiguration of Jesus. In Western Christianity, Elijah is commemorated as a saint with a feast day on 20 July by the Roman Catholic Church and the Lutheran Church–Missouri Synod. Catholics believe that he was unmarried and celibate. In the Eastern Orthodox Church and those Eastern Catholic Churches which follow the Byzantine Rite, he is commemorated on the same date (in the 21st century, Julian Calendar 20 July corresponds to Gregorian Calendar 2 August). He is greatly revered among the Orthodox as a model of the contemplative life. He is also commemorated on the Orthodox liturgical calendar on the Sunday of the Holy Fathers (the Sunday before the Nativity of the Lord). John the Baptist is also known as John the Forerunner in Christianity, John the Immerser in some Baptist Christian traditions, He is considered to be a prophet of God by all of these faiths, and is honoured as a saint in many Christian denominations. According to the New Testament, John anticipated a messianic figure greater than himself, and the Gospels portray John as the precursor or forerunner of Jesus, since John announces Jesus' coming and prepares the people for Jesus' ministry.
New drugs receive extensive scrutiny before FDA approval in a process called a new drug application (NDA). During the first Donald Trump presidency, the agency worked to make the drug-approval process go faster. Critics, however, argue that FDA standards are not sufficiently rigorous to prevent unsafe or ineffective drugs from getting approval. New drugs are available only by prescription by default. A change to over-the-counter (OTC) status is a separate process, and the drug must be approved through an NDA first. A drug that is approved is said to be "safe and effective when used as directed". Drugs being produced by a new manufacturer can be approved through one of two faster processes: the Abbreviated New Drug Application (ANDA) or the 505(b)(2) regulatory pathway for complex generic or biosimilar medications. Very rare, limited exceptions to this multi-step process involving animal testing and controlled clinical trials can be granted out of compassionate use protocols. This was the case during the 2015 Ebola epidemic with the use, by prescription and authorization, of ZMapp and other experimental treatments, and for new drugs that can be used to treat debilitating and/or very rare conditions for which no existing remedies or drugs are satisfactory, or where there has not been an advance in a long period of time.
Sources: en.wikipedia.org
Obsidian hydration dating (OHD) is a geochemical method of determining age in either absolute or relative terms of an artifact made of obsidian. Obsidian is a volcanic glass that was used by prehistoric people as a raw material in the manufacture of stone tools such as projectile points, knives, or other cutting tools through knapping, or breaking off pieces in a controlled manner, such as pressure flaking. Obsidian obeys the property of mineral hydration and absorbs water, when exposed to air at a well-defined rate. When an unworked nodule of obsidian is initially fractured, there is typically less than 1% water present. Over time, water slowly diffuses into the artifact forming a narrow "band", "rim", or "rind" that can be seen and measured with many different techniques such as a high-power microscope with 40–80 power magnification, depth profiling with SIMS (secondary ion mass spectrometry), and IR-PAS (infra red photoacoustic spectroscopy). In order to use obsidian hydration for absolute dating, the conditions that the sample has been exposed to and its origin must be understood or compared to samples of a known age (e.g. as a result of radiocarbon dating of associated materials).
In April 2020, Lilly announced they were investigating the use of baricitinib for treating people with COVID-19. The drug's anti-inflammatory activity was expected to act on the inflammatory cascade associated with COVID-19. In April and June 2020, the first two studies of baricitinib prescribed for hospitalized people with COVID-19 were published online. Then in November 2020, published research showed baricitinib was beneficial in treating people with COVID-19. According to the paper "mechanistic actions of a Janus kinase-1/2 inhibitor targeting viral entry, replication and the cytokine storm, and is associated with beneficial outcomes including in severely ill elderly people". In a clinical trial of hospitalized people with COVID-19, baricitinib, in combination with remdesivir, was shown to reduce time to recovery within 29 days after initiating treatment compared to participants who received a placebo with remdesivir. The data supporting the US Food and Drug Administration (FDA) emergency use authorization (EUA) for baricitinib combined with remdesivir was based on a randomized, double-blind, placebo-controlled clinical trial (ACTT-2), which was conducted by the US National Institute of Allergy and Infectious Diseases (NIAID). This clinical trial evaluated whether baricitinib impacted how long it took for subjects who were also taking remdesivir to recover from COVID-19.
== Bibliography == Christiano, A. M., Greenspan, D. S., Hoffman, G. G., Zhang, X., Tamai, Y., Lin, A.N., Dietz, H.C., Hovnanian, A., & Uitto, J (1993). A missense mutation in type VII collagen in two affected siblings with recessive dystrophic epidermolysis bullosa. Nature Genet. 462–66. Toriello, H. V., Glover, T. W., Takahara, K., Byers, P., Miller, D. E., Higgins, J. V., & Greenspan, D. S. (1996). A translocation interrupt the COL5A1 gene in a patient with Ehlers-Danlos syndrome and hypomelanosis of Ito. Nature Genet 13, 361–365. Kessler, E., Takahara, K., Biniaminov, L., Brusel, M., & Greenspan, D. S. (1996). Bone morphogenetic protein-1: the type I procollagen C-proteinase. Science, 271(5247), 360–362. Clark, T. G., Conway, S. J., Scott, I. C., Labosky, P. A., Winnier, G., Bundy, J., Hogan, B. L. M., & Greenspan, D. S. (1999). The mammalian tolloid-like 1 gene, Tll1, is necessary for normal septation and positioning of the heart. Development 126, 2631–2642. Scott, I. C., Blitz, I. L., Pappano, W. N., Maas, S. A., Cho, K. W. Y., & Greenspan, D. S. (2001). Twisted gastrulation homologs are extracellular cofactors in antagonism of BMP signaling. Nature 410, 475–478. Dart, M. L., Jankowska-Gan, E., Huang, G., Roenneburg, D. A., Keller, M. R., Torrealba, J. R., Rhoads, A., Marshall-Case, S., Kim, B., Bobadilla, J. L., Haynes, L. D., Wilkes, D. S., Burlingham, W. J., & Greenspan, D. S. (2010). IL-17-dependent autoimmunity to collagen type V in atherosclerosis. Circ Res 107, 1106–1116. Huang, G., Ge, G., Wang, D., Gopalakrishnan, B., Butz, D. H., Colman, R.
=== Nationwide === 99 Speedmart AEON Group AEON AEON MaxValu Prime AEON BiG (Formerly Carrefour) DAISO AgroBazaar Econsave Giant Hypermarket KK Mart Lotus's (Formerly Tesco, Tesco Extra) Mydin Eco-Shop MR.DIY
Sources: en.wikipedia.org
Purity is usually reported as an HPLC area percentage, most often measured at 214 nm. Identity is confirmed separately by mass spectrometry. A certificate of analysis should state both the method and the observed value.
Dry powder is kept frozen, desiccated, and shielded from light. Dissolved material is aliquoted and frozen to limit freeze-thaw cycles. Short-term refrigerated storage is common for working solutions.
Russia registers it as a prescription nasal product. Most other markets classify it as a research chemical with no approved medical use. Oversight of purity and labeling is consequently minimal in those markets.
It is a seven-amino-acid peptide, Thr-Lys-Pro-Arg-Pro-Gly-Pro, produced by chemical synthesis rather than extracted from biological tissue. Its design is based on tuftsin, a natural immunomodulatory tetrapeptide. The C-terminal Pro-Gly-Pro segment is a common stabilising motif in short regulatory peptides.